首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
对比维度 | 本产品 | 竞品常见问题 |
全长表达能力 | 支持 CXCL2 全长蛋白完整表达，确保蛋白结构完整性与功能活性。 | 部分产品仅能表达截短体，或全长表达成功率低，影响蛋白生物学功能验证。 |
活性保障 | 每批次均经细胞趋化、受体结合、SPR 等多维度活性验证，活性数据精确可溯源。 | 活性验证方式单一，或仅提供理论活性数据，实际实验中活性不稳定、重复性差。 |
标签选择多样化 | 提供 His、GST、荧光等多标签选择；支持人、小鼠、大鼠等多物种及野生型 / 突变型序列定制；可针对跨膜蛋白特定区域表达。 | 定制选项有限，难以满足复杂科研需求；跨膜蛋白表达技术不成熟，成功率低。 |
纯度与质控 | 出厂纯度默认≥90%，终产品纯度＞95%；内毒素＜0.1EU/μg，严格控制杂质与内毒素污染。 | 纯度波动大，杂质多导致实验背景干扰；内毒素含量高，易引发细胞或动物实验异常反应。 |
应用场景 | 可满足客户 SPR、体外实验、细胞实验、动物实验等多种类型，适配基础研究、药物开发等多领域需求。 | 仅能满足部分实验类型，难以支持综合性、跨平台的科研项目，需用户多次采购不同产品。 |
售后服务 | 提供实验全流程技术支持，涵盖实验设计、产品使用、数据解读；实验效果未达预期，提供解决方案或退换货服务。 | 售后响应慢，仅提供产品基础信息咨询；对实验失败无有效协助，用户需自行承担风险。 |
全长表达，突破研究瓶颈
活性保证，实验结果可靠
广泛应用，适配多元科研需求
全流程售后，科研无忧
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CXCL2 |
| Uniprot No | P19875 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 35-107aa |
| 氨基酸序列 | APLATELRCQCLQTLQGIHLKNIQSVKVKSPGPHCAQTEVIATLKNGQKA CLNPASPMVKKIIEKMLKNGKSN |
| 预测分子量 | 8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CXCL2重组蛋白的3篇参考文献示例(内容基于公开研究概括，非真实文献引用)：
---
1. **文献名称**：*Recombinant CXCL2 Chemokine: Structural Characterization and Neutrophil Activation*
**作者**：Smith A, et al.
**摘要**：本研究通过大肠杆菌表达系统制备了重组人CXCL2蛋白，分析了其二级结构及与CXCR2受体的结合特性。实验表明，重组CXCL2能有效诱导中性粒细胞迁移，并激活MAPK信号通路，提示其在炎症反应中的关键作用。
---
2. **文献名称**：*CXCL2 Promotes Tumor Angiogenesis in a Mouse Model of Colorectal Cancer*
**作者**：Zhang Y, et al.
**摘要**：通过重组CXCL2蛋白处理结肠癌小鼠模型，发现其显著促进肿瘤血管生成并加速肿瘤生长。研究揭示了CXCL2通过上调VEGF表达介导促血管生成机制，为靶向CXCL2的癌症治疗提供依据。
---
3. **文献名称**：*Role of Recombinant CXCL2 in Bacterial Clearance During Pneumonia*
**作者**：Lee JH, et al.
**摘要**：在小鼠肺炎模型中，外源性重组CXCL2增强了中性粒细胞向感染部位的募集，加速了细菌清除并减轻肺组织损伤，证实CXCL2在宿主防御感染中的保护性功能。
---
如需具体文献，建议通过PubMed或Web of Science检索关键词“recombinant CXCL2”获取最新研究。
CXCL2 (C-X-C motif chemokine ligand 2), also known as GROβ or MIP-2α, is a small, secreted protein belonging to the CXC chemokine family. It plays a critical role in inflammatory and immune responses by recruiting and activating neutrophils via binding to its receptor CXCR2. Structurally, it consists of approximately 73 amino acids in humans, with a conserved four-cysteine motif forming disulfide bonds essential for its tertiary structure and function. The protein is produced by various cell types, including macrophages, endothelial cells, and fibroblasts, in response to pro-inflammatory stimuli such as TNF-α, IL-1β, or bacterial lipopolysaccharides (LPS).
Recombinant CXCL2 protein is typically produced using expression systems like *E. coli* or mammalian cells, followed by purification steps to ensure high homogeneity and bioactivity. Its production enables researchers to study neutrophil chemotaxis, inflammatory pathways, and tissue repair mechanisms in controlled experimental settings. In disease contexts, CXCL2 is implicated in chronic inflammation, autoimmune disorders, and cancer progression, where excessive neutrophil infiltration can exacerbate tissue damage or promote tumor angiogenesis. For example, elevated CXCL2 levels are observed in conditions like rheumatoid arthritis, atherosclerosis, and certain metastatic cancers.
In research, recombinant CXCL2 is widely used to model inflammatory diseases *in vitro* or *in vivo*, screen anti-inflammatory drugs, or explore its dual role in wound healing versus pathological scarring. Its murine homolog, MIP-2. is often studied in preclinical models to mimic human CXCL2 functions. Despite its pro-inflammatory nature, CXCL2 also exhibits regenerative properties, making it a molecule of interest in balancing therapeutic interventions for inflammation-related disorders. Quality assessments, including SDS-PAGE, endotoxin testing, and functional assays (e.g., neutrophil migration), are critical to validate recombinant CXCL2 for experimental reproducibility.
×
